Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- HCV Patients May Be Able to Delay Therapy - MedPage Today
- HCV Patients May Be Able to Delay TherapyMedPage TodayThe addition of new protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) to previous standard therapy of interferon and ribavirin have significantly boosted sustained viral response for many patients, especially for blacks and Latinos,
- Too Little, Too Late for Achillion? - DailyFinance
- Too Little, Too Late for Achillion?DailyFinanceThe first drugs to improve hepatitis C treatment beyond the old standby of ribavirin and peginterferon were both protease inhibitors: Merck's (NYS: MRK) Victrelis and Vertex Pharmaceuticals' (NAS: VRTX) Incivek
- New research reveals effective treatments for gastrointestinal conditions - News-Medical.net
- New research reveals effective treatments for gastrointestinal conditionsNews-Medical
- Medivir: Interim Report, 1 January -- 31 March 2012 - MarketWatch (press release)
- Medivir: Interim Report, 1 January -- 31 March 2012MarketWatch (press release)Apart from interferon and ribavirin-free combination trials on TMC435 in phase II, this collaboration now also covers a phase III program Medivir opened 2012 with continued stable sales of Rx pharmaceuticals
- Twelve Weeks of GS-7977 Eliminates HCV as Well as 24 Weeks - Medscape
- Twelve Weeks of GS-7977 Eliminates HCV as Well as 24 WeeksMedscapeMay 2, 2012 (Barcelona, Spain) — Twelve weeks of GS-7977 (Gilead Sciences) plus pegylated interferon (pegIFN) and ribavirin was as effective as 24 weeks of treatment in eliminating hepatitis C virus (HCV) genotype 1
